The management of early-stage and metastatic triple-negative breast cancer: A review

Hematology/Oncology Clinics of North America

Volumn 27, Issue 4, 2013, Pages 737-749

  Anders, Carey K ^a   Zagar, Timothy M ^a   Carey, Lisa A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA mutation; Breast cancer; Chemotherapy; Radiation; Targeted agents; Triple negative

Indexed keywords

ANDROGEN RECEPTOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CLAUDIN 3; CLAUDIN 4; CLAUDIN 7; CYCLOPHOSPHAMIDE; EPIRUBICIN; ERIBULIN; FLUOROURACIL; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM; TEMOZOLOMIDE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ANTIANGIOGENIC THERAPY; BREAST CARCINOMA; BREAST METASTASIS; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; DIET; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; EXERCISE; GENE EXPRESSION; GENE MUTATION; LYMPH NODE METASTASIS; MASTECTOMY; MEDICAL DECISION MAKING; OVARY CANCER; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEOMICS; RECURRENCE FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

BRCA MUTATION; BREAST CANCER; CHEMOTHERAPY; RADIATION; TARGETED AGENTS; TRIPLE NEGATIVE;

FEMALE; HUMANS; NEOPLASM STAGING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84881314954     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.05.003     Document Type: Review

References (49)

1. Swain S. Triple-negative breast cancer: metastatic risk and role of platinum agents. 2008 ASCO Clinical Science Symposium. June 3, 2008.
2. Nielsen T., Hsu F., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374.
3. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
4. Smid M., Wang Y., Zhang Y., et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68(9):3108-3114.
5. Dent R., Trudeau M., Pritchard K., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15):4429-4434.
6. Livasy C., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19(2):264-271.
7. Hammond M.E., Hayes D.F., Dowsett M., et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. JClin Oncol 2010, 28(16):2784-2795.
8. Cheang M.C., Martin M., Nielsen T.O., et al. Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: a collaborative effort of the BIG-NCI NABCG. JClin Oncol 2012, 30. [abstract 1008].
9. Sorlie T., Perou C., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874.
10. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100(14):8418-8423.
11. Prat A., Perous C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5(1):5-23.
12. Lehmann B.D., Bauer J.A., Chen X., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. JClin Invest 2011, 121(7):2750-2767.
13. Gucalp A., Tolaney S., Isakoff S., et al. Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer TBCRC011. JClin Oncol 2012, 30. [abstract 1006].
14. Gonzalez-Angulo A.M., Timms K.M., Liu S., et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011, 17(5):1082-1089.
15. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
16. Haffty B.G., Yang Q., Reiss M., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. JClin Oncol 2006, 24(36):5652-5657.
17. Nguyen P.L., Taghian A.G., Katz M.S., et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. JClin Oncol 2008, 26(14):2373-2378.
18. Adkins F.C., Gonzalez-Angulo A.M., Lei X., et al. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 2011, 18(11):3164-3173.
19. Abdulkarim B.S., Cuartero J., Hanson J., et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. JClin Oncol 2011, 29(21):2852-2858.
20. Wang J., Shi M., Ling R., et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiother Oncol 2011, 100(2):200-204.
21. Huang E.H., Tucker S.L., Strom E.A., et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. JClin Oncol 2004, 22(23):4691-4699.
22. McGuire S.E., Gonzalez-Angulo A.M., Huang E.H., et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007, 68(4):1004.
23. Gonzalez-Angulo A.M., Litton J.K., Broglio K.R., et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. JClin Oncol 2009, 27(34):5700-5706.
24. Ho A.Y., Gupta G., King T.A., et al. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer 2012, 118(20):4944-4952.
25. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. JClin Oncol 2006, 24(13):2019-2027.
26. Carey L., Dees E., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13(8):2329-2334.
27. Liedtke C., Mazouni C., Hess K., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. JClin Oncol 2008, 26(8):1275-1281.
28. Silver D., Richardson A., Eklund A., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. JClin Oncol 2010, 28(7):1145-1153.
29. Byrski T., Gronwald J., Huzarski T., et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Hered Cancer Clin Pract 2011, 9(2):A4.
30. von Minckwitz G., Eidtmann H., Rezai M., et al. Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer. NEngl J Med 2012, 366(4):299-309.
31. Bear H.D., Tang G., Rastogi P., et al. NSABP Protocol B-40: the effect on pCR of Bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy. JClin Oncol 2011, 29. LBA #1005.
32. Cameron D, Brown J, Dent R, etal. Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Paper presented at: Cancer Therapy and Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium, San Antonio, TX, 2012.
33. Balko JM, Wang K, Sanders ME, etal. Profiling of triple negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease. Paper presented at: American Association for Cancer Research San Antonio Breast Cancer Symposium, San Antonio, TX, 2012.
34. Cheang M.C., Voduc K.D., Tu D., et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC. CTG MA. 5 randomized trial. Clin Cancer Res 2012, 18(8):2402-2412.
35. Rugo HS, Barry WT, Moreno-Aspitia A, etal. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). Paper presented at: 2012 Annual ASCO Meeting, Chicago, IL, 2012.
36. Kaufmann P, Awada A, Twelves C, etal. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Paper presented at: San Antonio Breast Cancer Symposium, San Antonio, TX, 2012.
37. Isakoff S., Goss P., Mayer E., et al. TBCRC009: a multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. JClin Oncol 2011, 29. Abstract 1025.
38. Baselga J., Stemmer S., Pego A., et al. Cetuximab+ Cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res 2010, 70(24). [abstract PD 01-10].
39. O'Shaughnessy J., Miles D., Gray R.J., et al. Ameta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). JClin Oncol 2010, 28(15s). [abstract 1005].
40. Gelmon K.A., Tischkowitz M., Mackay H., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12(9):852-861.
41. Isakoff S.J., Overmoyer B., Tung N.M., et al. Aphase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. JClin Oncol 2010, 28(15s). [asbtract 1019].
42. Carey L.A., Rugo H.S., Marcom P.K., et al. TBCRC 001: randomized phase II study of Cetuximab in combination with Carboplatin in stage IV triple-negative breast cancer. JClin Oncol 2012, 30(21):2615-2623.
43. Marty B., Maire V., Gravier E., et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008, 10(6):R101.
44. Chen M., Ryan C., Piwnica-Worms H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol 2003, 23(21):7488-7497.
45. Ma C.X., Cai S., Li S., et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. JClin Invest 2012, 122(4):1541-1552.
46. Roberts P.J., Usary J., Darr D., et al. Combined PI3K/mTOR and MEK inhibition provides broad anti-tumor activity in faithful murine cancer models. Clin Cancer Res 2012, 18(19):5290-5303.
47. Duncan J.S., Whittle M.C., Nakamura K., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149(2):307-321.
48. Tate C.R., Rhodes L., Segar H., et al. Targeting triple-negative breast cancer cells with the HDAC inhibitor Panobinostat. Breast Cancer Res 2012, 14(3):R79.
49. Connolly R.M., Jeter S., Zorzi J., et al. Amulti-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBCRC008). JClin Oncol 2010, 28(15s). [abstract TPS111].